Dr. Ryan Ribeiro cited data from Israel suggesting that the first dose of the COVID-19 vaccine may only provide 33% protection, raising concerns about delaying second doses. Pfizer announced plans to study the necessity of a third "booster" dose within six to twelve months to combat new variants like the South African strain. This shift suggests a transition toward a permanent, recurring vaccination model.
